A Contemporary Approach to Dysmenorrhea in Adolescents

Dysmenorrhea is the most common gynecologic complaint among adolescent girls. Despite progress in understanding the physiology of dysmenorrhea and the availability of effective treatments, many adolescent girls do not seek medical advice or are undertreated.Dysmenorrhea in adolescents is usually primary (functional), and is associated with normal ovulatory cycles and no pelvic pathology. In approximately 10% of adolescents with severe dysmenorrhea, pelvic abnormalities such as endometriosis or uterine anomalies may be found. Potent prostaglandins from the second series and potent leukotrienes from the fourth series play an important role in generating dysmenorrhea symptoms.Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common pharmacologic treatment for dysmenorrhea. A loading dose of NSAIDs (typically twice the regular dose) should be used as initial treatment for dysmenorrhea in adolescents followed by a regular dose until symptoms abate. Adolescents with symptoms that do not respond to treatment with NSAIDs for three menstrual periods should be offered combined estrogen/progestin oral contraceptive pills for three menstrual cycles. Adolescents with dysmenorrhea who do not respond to this treatment should be evaluated for secondary causes of dysmenorrhea.Adolescent care providers have the important roles of educating adolescent girls about menstruation-associated symptoms, as well as evaluating and effectively treating patients with dysmenorrhea.

[1]  L. Golub,et al.  Exercise and dysmenorrhea in young teenagers: A 3-year study. , 1968, Obstetrics and gynecology.

[2]  D. Mishell,et al.  Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. , 1977, The Journal of clinical endocrinology and metabolism.

[3]  D. M. Potts,et al.  Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. , 1977, British medical journal.

[4]  V. Lundström,et al.  Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. , 1978, American journal of obstetrics and gynecology.

[5]  W. Chan,et al.  Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. , 1978, Prostaglandins.

[6]  M. Henzl,et al.  Naproxen Sodium in Dysmenorrhea: Its Influence in Allowing Continuation of Work/School Activities , 1978, Obstetrics and gynecology.

[7]  S. Emans,et al.  New insights into the old problem of chronic pelvic pain. , 1979, Journal of pediatric surgery.

[8]  P. Bergsjø SOCIOECONOMIC IMPLICATIONS OF DYSMENORRHEA , 1979, Acta obstetricia et gynecologica Scandinavica. Supplement.

[9]  Dawood My,et al.  Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. , 1980 .

[10]  J. Simpson,et al.  Heritable aspects of endometriosis. I. Genetic studies. , 1980, American journal of obstetrics and gynecology.

[11]  I. Litt,et al.  Epidemiology of adolescent dysmenorrhea. , 1981, Pediatrics.

[12]  J. Powell,et al.  Intrauterine pressure changes during dysmenorrhea therapy. , 1982, American journal of obstetrics and gynecology.

[13]  Chatman Dl,et al.  Endometriosis in adolescents. , 1982 .

[14]  I. Milsom,et al.  An epidemiologic study of young women with dysmenorrhea. , 1982, American journal of obstetrics and gynecology.

[15]  I. Litt,et al.  Current status of the etiology and management of dysmenorrhea in adolescence. , 1982, Pediatrics.

[16]  P. Budoff Zomepirac sodium in the treatment of primary dysmenorrhea syndrome. , 1982, The New England journal of medicine.

[17]  S. Roy A Double-Blind Comparison of a Propionic Acid Derivative (Ibuprofen) and a Fenamate (Mefenamic Acid) in the Treatment of Dysmenorrhea , 1983, Obstetrics and gynecology.

[18]  H. Bratt,et al.  Clinical Experience with a Triphasic Oral Contraceptive , 1984, Acta obstetricia et gynecologica Scandinavica.

[19]  P. Owen Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. , 1984, American journal of obstetrics and gynecology.

[20]  I. Milsom,et al.  Effect of various oral contraceptive combinations on dysmenorrhea. , 1984, Gynecologic and obstetric investigation.

[21]  S. Levinson Peptidoleukotriene binding in guinea pig uterine membrane preparations. , 1984, Prostaglandins.

[22]  L. Demers,et al.  Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea , 1984, British journal of obstetrics and gynaecology.

[23]  C. W. Linder,et al.  Factors influencing adolescents' responses to regimens of naproxen for dysmenorrhea. , 1985, American journal of diseases of children.

[24]  T. Pugsley,et al.  Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. , 1986, Prostaglandins, leukotrienes, and medicine.

[25]  M. Forsling,et al.  Plasma concentrations of vasopressin and a prostaglandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with a combined oral contraceptive. , 1987, The Journal of endocrinology.

[26]  H. Morris,et al.  Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. , 1987, The Journal of endocrinology.

[27]  D. Mehlisch Ketoprofen, Ibuprofen, and Placebo in the Treatment of Primary Dysmenorrhea: A Double‐Blind Crossover Comparison , 1988, Journal of clinical pharmacology.

[28]  J. Johnson Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. , 1988, Journal of adolescent health care : official publication of the Society for Adolescent Medicine.

[29]  Dawood My Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. , 1988 .

[30]  T. Laudański,et al.  Effect of an oral contraceptive in primary dysmenorrhea--changes in uterine activity and reactivity to agonists. , 1989, Contraception.

[31]  Mehlisch Dr Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea. , 1990 .

[32]  G. Creatsas,et al.  Prostaglandins: PGF2α, PGE2, 6-keto-PGF1α and TXB2 serum levels in dysmenorrheic adolescents before, during and after treatment with oral contraceptives , 1990 .

[33]  A. Simopoulos Omega-3 fatty acids in health and disease and in growth and development. , 1991, The American journal of clinical nutrition.

[34]  J. Rock,et al.  The role of laparoscopy in the treatment of endometriosis. , 1991, Fertility and sterility.

[35]  S. Nigam,et al.  Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. , 1991, Eicosanoids.

[36]  M. Forsling,et al.  Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment—effect on uterine contractility , 1992 .

[37]  I. Milsom,et al.  The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. , 1992, Contraception.

[38]  C. Nathanson,et al.  Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. , 1992, American journal of obstetrics and gynecology.

[39]  F. Weber-Diehl,et al.  Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. , 1992, Contraception.

[40]  M. Forsling,et al.  Stimulation of vasopressin release in women with primary dysmenorrhea and after oral contraceptive treatment — Effect on uterine contractility , 1993, British journal of obstetrics and gynaecology.

[41]  G. D. Davis,et al.  Clinical characteristics of adolescent endometriosis. , 1993, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[42]  L. Fedele,et al.  Comparative efficacy of diclofenac dispersible 50 mg and ibuprofen 400 mg in patients with primary dysmenorrhea. A randomized, double-blind, within-patient, placebo-controlled study. , 1995, International journal of clinical pharmacology and therapeutics.

[43]  C. Kainz,et al.  Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. , 1995, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[44]  B. Deutch Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake. , 1995, European journal of clinical nutrition.

[45]  F. Biro,et al.  Depo-Provera in adolescents: effects of early second injection or prior oral contraception. , 1995, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[46]  F. Biro,et al.  Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. , 1996, American journal of obstetrics and gynecology.

[47]  S. Harlow,et al.  A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women , 1996, British journal of obstetrics and gynaecology.

[48]  S. Lurie,et al.  Clinical evaluation of a new model of a transcutaneous electrical nerve stimulation device for the management of primary dysmenorrhea. , 1997, Gynecologic and obstetric investigation.

[49]  A. Matsuki,et al.  Analgesic effect of a herbal medicine for treatment of primary dysmenorrhea--a double-blind study. , 1997, The American journal of Chinese medicine.

[50]  T. Kuehl,et al.  Extending the Duration of Active Oral Contraceptive Pills to Manage Hormone Withdrawal Symptoms , 1997, Obstetrics and gynecology.

[51]  M. Canis,et al.  Revised American Society for Reproductive Medicine classification of endometriosis: 1996. , 1997, Fertility and sterility.

[52]  P. McGrath,et al.  Use of medication by adolescents for the management of menstrual discomfort. , 1997, Archives of pediatrics & adolescent medicine.

[53]  S. Emans,et al.  Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. , 1997, Journal of pediatric and adolescent gynecology.

[54]  J. Drazen,et al.  Urinary Leukotriene (LT)- E4 in Adolescents with Dysmenorrhea , 1998 .

[55]  C. Gordon,et al.  "Add-back" therapy for endometriosis in adolescents. , 1998, The Journal of reproductive medicine.

[56]  C. Weinberg,et al.  Vegetable consumption and risk of chronic disease , 1998 .

[57]  P. McGrath,et al.  Non-pharmacologic strategies used by adolescents for the management of menstrual discomfort. , 1999, The Clinical journal of pain.

[58]  S. Daniels,et al.  Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. , 1999, Obstetrics and gynecology.

[59]  M. Laufer,et al.  Endometriosis in adolescents. Incidence, diagnosis and treatment. , 1999, The Journal of reproductive medicine.

[60]  J. Keogh,et al.  Primary dysmenorrhea in young Western Australian women: prevalence, impact, and knowledge of treatment. , 1999, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[61]  E. Cassese,et al.  Influence of menstrual factors and dietary habits on menstrual pain in adolescence age. , 2000, European journal of obstetrics, gynecology, and reproductive biology.

[62]  J. Drazen,et al.  Urinary leukotriene (LT) E(4) in adolescents with dysmenorrhea: a pilot study. , 2000, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[63]  J. Guillebaud Reducing withdrawal bleeds , 2000, The Lancet.

[64]  S. Kelder,et al.  Prevalence and impact of dysmenorrhea on Hispanic female adolescents. , 2000, Archives of pediatrics & adolescent medicine.

[65]  R. Smith Continuous topical heat was as effective as ibuprofen for dysmenorrhoea Akin MD,Weingand KW,Hengehold DA,et al. Continuous low›level topical heat in the treatment of dysmenorrhea.Obstet , 2001 .

[66]  Roger P. Smith,et al.  Continuous Low‐Level Topical Heat in the Treatment of Dysmenorrhea , 2001, Obstetrics and gynecology.

[67]  D. Cox,et al.  Behavioral treatment parameters with primary dysmenorrhea , 1978, Journal of Behavioral Medicine.